Investing in Healthcare
Investing in Healthcare

How Have the Top Healthcare ETFs Performed in 2026?

Below, we compare eight of the largest healthcare ETFs on performance, cost, and what they actually hold.

Total returns (market price) from ETF.com fund pages, as of Nov. 3, 2026. AUM and expense ratios from ETF.com.

The spread between the best and worst fund is about 35.5 percentage points: IBB is up 26.79% YTD, while IHI is down 8.72%. The four broad U.S. sector funds (XLV, IYH, FHLC and VHT) are within about one percentage point of each other year to date.

Why Are Biotech ETFs IBB and XBI Leading?

IBB is up 26.79% YTD and 34.41% over the past year, and XBI is up 24.82% YTD and 35.47% over one year, the strongest one-year return in the group. Both are well ahead of the broad sector funds. The recent trend has diverged, though. Over the past month, IBB gained 4.14%, while XBI slipped 1.54%. Over three months, IBB returned 14.69% versus 3.43% for XBI.

The difference comes down to construction. IBB is weighted toward large biotech companies, with its top 10 holdings making up 51.84% of the fund, led by Gilead Sciences (9.08%), Amgen (8.44%), Vertex Pharmaceuticals (7.92%) and Regeneron (6.58%). XBI uses a modified equal-weight approach across 158 holdings, so its top 10 account for only 18.18% of assets and no single stock exceeds about 2.4%. That gives XBI far more exposure to small and mid-cap biotech, which tends to move more sharply in both directions.

Which Broad Healthcare ETF Is Best?

The broad funds delivered nearly identical results so far in 2026:

  • XLV: 20.72% YTD, 0.08% expense ratio, $49.19B AUM

  • IYH: 20.20% YTD, 0.37% expense ratio, $4.71B AUM

  • FHLC: 19.99% YTD, 0.08% expense ratio, $3.95B AUM

  • VHT: 19.77% YTD, 0.09% expense ratio, $20.80B AUM

XLV edged out the group, and its holdings may help explain why. It draws only from the S&P 500, so it is more concentrated: 63 holdings, with the top 10 at 61.55% of the fund and Eli Lilly alone at 16.92%. VHT holds 411 stocks, with a 51.75% top-10 weight and a 12.93% Eli Lilly position. In fact, the four broad funds rank YTD in the same order as their Eli Lilly weightings (XLV 16.92%, IYH 16.39%, FHLC 14.62%, VHT 12.93%), suggesting the more mega-cap-heavy portfolios have had a slight edge this year, though the gaps are small.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *